Clinical trials: Steatosis of Liver
Hepatic Steatosis
Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
The objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults.
- Trial name
- BIPEH (NCT06394206)
- Testing
- Specialized Unit, Usual Follow-Up
- Where
- Spain
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis
Quantitative Ultrasound (RS85 and R20) for Liver Fat Quantification in MASLD Using MRI-PDFF as Reference
This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat quantification in patients with metabolic…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
- Trial name
- DeepUSFF (NCT07192159)
- Testing
- Quantitative ultrasound (DeepUSFF)
- Where
- 2 sites in United States, South Korea
- Volunteers
- 182 people
- Sponsor
- Seoul National University Hospital
Diabetes, Steatosis of Liver
Biomarkers of Steatohepatitis in Type 2 Diabetes Patients
The aims of the study are to identify a subgroup of type 2 diabetics at risk of developing and progressing to non-alcoholic steatohepatitis (NASH), to correlate clinical and laboratory parameters with sonographic and…
- Trial name
- STEDIB (NCT07098520)
- Testing
- No intervention, just observation
- Where
- 2 sites in Czechia
- Volunteers
- 100 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)
The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics on hepatic fat content as measured by biochemichal hepatic steatosis indeces, serum…
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease, Hepatic Steatosis
- Trial name
- NCT06352697
- Testing
- Probiotic lysate (postbiotic and metabiotc)
- Where
- 5 sites in Ukraine
- Volunteers
- 52 people
- Sponsor
- Bogomolets National Medical University
Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
The purpose of this study is to evaluate the efficacy and safety of a short-term (12-week) prehabilitation strategy combining mazdutide (a novel GLP-1/GCG receptor dual agonist) with lifestyle optimization, compared to lifestyle…
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
- Trial name
- PRIME (NCT07718126)
- Testing
- Mazdutide, Lifestyle Optimization
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Liver Fibrosis, Liver Steatosis
The Sonic Incytes Liver Incyte System, Assessment of Liver Fibrosis and Steatosis
Evaluate the feasibility of the Liver Incyte system for liver elasticity measurement in healthy volunteers and patients with liver fibrosis.
- Trial name
- NCT03957070
- Testing
- Liver Incyte
- Where
- 2 sites in United States, Canada
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sonic Incytes
Hepatic Steatosis, NAFLD
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less…
- Conditions
- Hepatic Steatosis, NAFLD, Adolescent Obesity
- Trial name
- AMINOS (NCT05935826)
- Testing
- Essential Amino Acid Supplement by Amino Co
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes, Hepatic Steatosis
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).
- Trial name
- ACELERATE-P (NCT06993454)
- Testing
- Magnetic Resonance Liver Assessment, Bike Exercise VO2max, DEXA
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
MASLD (Metabolic dysfunction-associated steatotic liver disease) is a condition where fat builds up in the liver. It is the most common cause of liver disease worldwide.
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis, Steatosis of Liver
- Trial name
- FLOURISH (NCT07013916)
- Testing
- fructose, glucose
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Steatosis of Liver, Metabolic Liver Injury
Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity
This single-center, retrospective observational cohort study evaluated early changes in non-invasive hepatic and metabolic indices (FIB-4, APRI, HSI, and the triglyceride-glucose [TyG] index) in adults with overweight or obesity…
- Conditions
- Steatosis of Liver, Metabolic Liver Injury, Obesity, Overweight
- Trial name
- GLP-NIT (NCT07701005)
- Testing
- Semaglutide, Tirzepatide
- Where
- Turkey (Türkiye)
- Volunteers
- 154 people
- Sponsor
- Goztepe Prof Dr Suleyman Yalcın City Hospital
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults NAFLD Patients (DELI_NAFLD Study)
The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics on hepatic fat content as measured by MRI-PDFF and ultrasonography, liver stiffness (LS)…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Hepatic Steatosis, Fatty Liver
- Trial name
- NCT05804422
- Testing
- Probiotic lysate (postbiotic and metabiotc)
- Where
- 4 sites in Ukraine
- Volunteers
- 39 people
- Sponsor
- Bogomolets National Medical University
Steatosis of Liver
Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.
The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical…
- Trial name
- MASLD (NCT07652892)
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Liver Steatosis
Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis
Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition.
- Trial name
- TRANSTEATOSE (NCT02575625)
- Testing
- Fibroscan, Blood test for biological assessment of liver function, MRI
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
MAFLD, Liver Fibrosis
Incidence of Liver Disease-Related Outcomes in People With HIV
Antiretroviral therapy can effectively control the replication of HIV, prolong the lifespan of patients infected with HIV, and improve their quality of life.At the same time, non-AIDS-related diseases such as diabetes and chronic…
- Conditions
- MAFLD, Liver Fibrosis, MASH, HIV
- Trial name
- PWH (NCT06940375)
- Testing
- Abdominal ultrasound , Fibroscan and body composition analysis examination
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Shanghai Public Health Clinical Center
Liver Steatosis
STANDARDIZATION OF THE PROTOCOL FOR ATTENUATION COEFFICIENT MEASUREMENT
The assessment of liver fat content is important in patients suspected of or diagnosed with chronic liver disease. Non-alcoholic fatty liver disease (NAFLD) is defined by the presence of hepatic fat content ≥5% of hepatocytes.
- Trial name
- NCT07616843
- Where
- Italy
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver
Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
Hepatic steatosis is a common radiographic "incidental finding" that is overlooked and underreported to patients. The investigators developed a clinical decision support system using machine learning and natural language…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- STIRRED (NCT06944353)
- Testing
- STIRRED
- Where
- United States
- Volunteers
- 4,704 people
- Sponsor
- Northwestern University
Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease
Interventional AI-Human Collaboration for Steatotic Liver Disease Screening
Steatotic liver disease (SLD) is one of the most prevalent chronic liver diseases worldwide, affecting nearly 30% of the global population and projected to exceed 55% by 2040.
- Conditions
- Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT07613827
- Testing
- AI-human collaboration for SLD screening
- Where
- China
- Volunteers
- 7,969 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Elastography, Shear Wave Elastography
HIBOC = Hepatic Imaging Biomarkers in Obese Children
The goal of this prospective, diagnostic observational study is to learn about how imaging based markers for components of liver disease appear in children with obesity.
- Conditions
- Elastography, Shear Wave Elastography, Shear Wave Dispersion, Attenuation Imaging
- Trial name
- NCT06463223
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Sahlgrenska University Hospital
Diabetes Mellitus, Type 2, Liver Fibrosis
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and…
- Conditions
- Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis
- Trial name
- MEDFAST (NCT06845345)
- Testing
- early time restricted Mediterranean diet, Mysimba
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Carmen Dietvorst
Healthy Volunteers, Hepatic Steatosis
Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis (increased liver fat and suspected inflammation).
- Trial name
- NCT06891365
- Testing
- NNC0581-0001
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S